`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`SEQUENOM, INC.
`Petitioner
`
`V.
`
`THE BOARD OF TRUSTEES OF
`
`THE LELAND STANFORD JUNIOR UNIVERSITY
`
`Patent Owner
`
`Case IPR2013-0039O
`
`Patent 8,195,415
`
`AFFIDAVIT OF MICHAEL J. MALECEK
`
`Page 1 of4
`
`SEQUENOM EXHIBIT 1012
`
`Sequenom v. Stanford
`Trial |PR2013-00390
`
`SEQUENOM EXHIBIT 1012
`Sequenom v. Stanford
`Trial IPR2013-00390
`
`Page 1 of 4
`
`
`
`1.
`
`I, Michael J. Malecek, am more than twenty-one years of age, am
`
`competent to present this affidavit, and have personal knowledge of the facts set forth
`
`herein.
`
`2.
`
`This affidavit is given in support of Petitioner Sequenom, Inc’s Motion
`
`for Pro Hac Vice Admission of Michael J. Malecek.
`
`3.
`
`I am a partner at the law firm of Kaye Scholer LLP. I am an experienced
`
`litigation attorney and have been a litigation attorney for more than twenty years.
`
`4.
`
`5.
`
`6.
`
`I have been litigating patent cases for over eleven years.
`
`I am a member in good standing of the State Bar of California.
`
`I have never been suspended or disbarred from practice before any court
`
`or administrative body.
`
`7.
`
`No court or administrative body has ever denied my application for
`
`admission to practice before it.
`
`8.
`
`No court or administrative body has ever imposed sanctions or contempt
`
`citations on me.
`
`9.
`
`I have read and will comply with the Office Patent Trial Practice Guide
`
`and the Board’s Rules of Practice for Trials set forth in part 42 of the Code of Federal
`
`Regulations.
`
`10.
`
`I understand that I will be subject to the USPTO Code of Professional
`
`Responsibility set forth in 37 CPR. §§ 10.20 et seq. and disciplinary jurisdiction
`
`under 37 C.'F.R. § 11.19(a).
`
`Page 2 of 4
`
`Page 2 of 4
`
`Page 2 of 4
`
`
`
`11.
`
`I was admitted pro hac vice by the Board in Case IPR2012-00022
`
`(MPT) to represent the Patent Owner as back-up counsel in that proceeding.
`
`12.
`
`l have an established familiarity with the subject matter at issue in this
`
`proceeding.
`
`I have litigated patent cases in the area of nucleic acid analysis since
`
`2002, including several cases about “next generation” sequencing technologies.
`
`I
`
`began representing and advising real party in
`
`interest Sequenom,
`
`Inc.
`
`(“Sequenom”) in matters relating to US. Patent No. 8,195,415 (“the ’415 patent”)
`
`no later than June 2012. Since that time, I have become very familiar with the
`
`’4 1 S patent and with its prosecution file history.
`
`13.
`
`I am lead trial counsel for Sequenom in its co—pending district court
`
`litigation against the Patent Owner and its licensee Verinata Health, Inc. That
`
`litigation is captioned Verz'nat‘a Health, Inc, et a]. v. Sequenom, Inc, et cl, Case
`
`No. 12-cv-00865 (SI) (N.D. Cal), and involves the same patent at issue in this
`
`proceeding. As lead trial counsel for Sequenom, I have been actively involved in
`
`all aspects of the co-pending district court litigation. As examples of my work as
`
`lead trial counsel,
`
`I have presented a technology tutorial and argued claim
`
`construction regarding the ”415 patent before the District Court in 2013.
`
`14.
`
`In addition, I am lead trial counsel for Sequenom in two other pending
`
`district court cases involving related technology claimed in US. Patent No.
`
`6,258,540 (“the ’540 patent”): Ariosa Diagnostics, Inc. v. Sequenom, Inc. e! 611.,
`
`Page 3 of 4
`
`Page 3 of 4
`
`Page 3 of 4
`
`
`
`Civ. No. 11-06391-SI (ND. Cal.); and Narera, Inc. v. Sequenom, Inc. et al., Civ.
`
`No. 12-00132-SI (ND. Cal). Further, in January 2013, I argued on behalf of
`
`Sequenom in an appeal before the Court of Appeals for the Federal Circuit relating
`
`to the validity and proper claim construction of the ’540 patent in Aria Diagnostics,
`
`Inc. V. Sequenom, Inc., Appeal No. 12-1531.
`
`
`
`Sworn
`and subscribed before me
`thisi day of January, 2014.
`
`
`
`Notary Public
`
`
`
`Page 4 of 4
`
`Page 4 of 4
`
`Page 4 of 4
`
`